-+ 0.00%
-+ 0.00%
-+ 0.00%

Monte Rosa's MRT-51443 Demonstrates Potent CDK2 Degradation And Delays Resistance To CDK4/6 Inhibitors In Preclinical Studies

Benzinga·04/28/2025 11:03:54
Listen to the news

CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy

CDK2 MGD delayed resistance to CDK4/6 inhibition in vitro and displayed superior selectivity versus clinical-stage CDK2 inhibitors